IKAP Stock Chart & Stats
€12.88
-€0.28(-2.09%)
At close: 4:00 PM EDT
€12.88
-€0.28(-2.09%)
Day’s Range― - ―
52-Week Range€7.76 - €16.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.67B
Enterprise Value€1.73K
Total Cash (Recent Filing)€378.78M
Total Debt (Recent Filing)€68.64M
Price to Earnings (P/E)6.6
Beta0.19
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.24
Shares Outstanding128,601,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.77Price Target Upside6.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.83
Revenue Forecast (FY)€285.94M
Bulls Say, Bears Say
Bulls Say
Profitability & Cash FlowImproved and sustained profitability and free cash flow since 2024 provide durable internal funding for commercialization, R&D and operating needs. Strong cash conversion reduces reliance on external financing and supports predictable capital allocation and operational resilience over the medium term.
Balance Sheet StrengthLow leverage and a substantial equity base give Aurinia financial flexibility to fund operations, absorb biotech‑cycle shocks, and pursue strategic moves without immediate heavy dilution. A sound balance sheet underpins longer‑term commercial execution and provides optionality for targeted investments or acquisitions.
Pipeline Expansion (Kezar)Completing the Kezar acquisition brings zetomipzomib and other assets into Aurinia’s autoimmune pipeline, diversifying its product mix beyond LUPKYNIS. This strengthens long‑term growth optionality and reduces single‑product exposure if development and commercialization of new candidates progress as planned.
Bears Say
Earnings VolatilityHigh historical earnings and cash‑flow volatility means recent profits may not persist. Biotech revenue swings and episodic non‑recurring items have driven ROE and margins to alternate extremes, increasing execution and forecasting risk that could reverse cash generation in adverse periods.
Single‑Product ConcentrationRevenue dependence on a single marketed product leaves Aurinia exposed to prescription volume, pricing pressure, payer coverage and competitive entrants. This concentration creates sustained sensitivity to reimbursement decisions and market access outcomes, posing downside to revenue durability.
Acquisition Integration & Contingent LiabilitiesThe Kezar deal carries contingent value rights and cash consideration, creating potential future obligations and integration demands. Near‑term cash drain, added R&D commitments and program execution risk could strain resources and complicate capital allocation, pressuring margins if development timelines slip.
Aurinia Pharmaceuticals News
IKAP FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was €7.76 and its highest was €16.39 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is €1.67B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 89 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 128,601,670 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:IKAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.77 (6.92% Upside)
€13.77 (6.92% Upside)
Blogger Sentiment
Bullish
DE:IKAP Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.41%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
IKAP Revenue Breakdown
90.00% U.S.
10.00% Japan
IKAP Stock 12 Month Forecast
Average Price Target
€13.77
▲(6.92% Upside)